Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirius: Ultevursen in Advanced USH2A-Mediated Retinitis Pigmentosa
NCT05158296Phase 3Terminated
- Sponsor
- Laboratoires Théa
- Start
- Dec 2021
- Primary completion
- Oct 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 4
01
Overview
A Phase 3 trial of ultevursen in retinitis pigmentosa (RP), Usher syndrome type 2A (USH2A), sponsored by Laboratoires Théa. Started Dec 2021; status: terminated.
02
Drugs
ultevursen
03
Conditions
retinitis pigmentosa (RP)Usher syndrome type 2A (USH2A)
Beyond the preview
Go deeper on NCT05158296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05158296.